Recombinant SARS-CoV-2 Nucleocapsid Protein

Lateral flow, indirect ELISA, sandwich ELISA, glycosylation analysis, antibody generation, hybridoma screening, western blotting, biotin/dye/bead conjugation, binder selection, crystallization, and vaccine development. Sandwich ELISA: this protein functions as a standard in conjunction with 130-10781 (capture antibody) and 130-10761 (detection antibody).

C-terminal his-tag

-20°C

Recombinant SARS-CoV-2 Nucleocapsid Protein with C-terminal His-tag, derived from the transfected human HEK293 cells. Datasheet

12352202

Met1-Ala419

His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)

Figure 1. Deglycosylation of purified recombinant proteins. Purified proteins were untreated (Lane 2) or treated with Protein Deglycosylation Kit under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one major band at the expected size (47 kDa), thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.Lane 1: Protein standard ladder (kDa)Lane 2: Untreated protein under reducing conditions. Shown one ˆ¼55 kDa major band (red arrow) and 25-30 kDa multiple of minor bands (green arrows). This small bands are likely cleavage products. All bands were confirmed by Western blotting (Lane 5). Other minor large bands (>80 kDa) may be the trace amount of copurified proteins from host cells.Lane 3: Treated protein with deglycosylation enzymes under native conditions. Shown one 47 kDa major band (red arrow) and two minor 22-30 kDa bands (green arrows).Lane 4: Treated protein with deglycosylation enzymes under reducing conditions. Shown one 47 kDa major band (red arrow) and two minor 22-30 kDa bands (green arrows).Lane 5: Western blotting analysis of Lane 1. Shown two major reaction bands (red arrow, green arrow).